Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Patricia Bozeman

Nurse Practitioner Hartford, CT Nurse Practitioner

NPI 1376538074 CMS profile 10575110

85 Seymour St, Hartford, CT 06106

Open in the dashboard

General payments

$10,787

181 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Patricia Bozeman of Hartford, CT is reported in the CMS Open Payments database as having received $10,787 across 181 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $6,662 15
2024 General $1,250 23
2023 General $1,053 40
2022 General $1,051 58
2021 General $772 45

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Patricia Bozeman
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Patricia Bozeman were reported at $6,662. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Patricia Bozeman Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $772 $135 $40–$426 $132
2022 $1,051 $152 $48–$470 $149
2023 $1,053 $166 $54–$529 $160
2024 $1,250 $173 $55–$556 $164
2025 $6,662 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Tactile Systems Technology Inc $9,722 163 payments
  2. Silk Road Medical, Inc. $641 6 payments
  3. Janssen Pharmaceuticals, Inc $269 7 payments
  4. Janssen Scientific Affairs, LLC $78 2 payments
  5. Koya Medical, Inc. $40 1 payment
  6. Smith+Nephew, Inc. $38 2 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $4,425 5 payments
  2. Food and Beverage $3,739 164 payments
  3. Travel and Lodging $1,775 2 payments
  4. Consulting Fee $488 2 payments
  5. Compensation for serving as faculty or as a speaker for a medical education program $200 1 payment
  6. Education $160 7 payments
Products named General payments · program years 2021–2025
  1. Flexitouch Plus $9,642 160 payments
  2. Nimbl $6,622 14 payments
  3. Entre Plus $1,670 57 payments
  4. entre Pneumatic Compressor $1,350 89 payments
  5. ENROUTE Transcarotid Stent $641 6 payments
  6. ENROUTE Transcarotid Neuroprotection System Cardiology/Vascular Diseases $641 6 payments
  7. ENROUTE Enflate Transcarotid RX Balloon Dilatation Catheter $482 3 payments
  8. ENROUTE Transcarotid Neuroprotection System Cardiology/Vascular Diseases $482 3 payments
  9. XARELTO $347 9 payments
  10. Entre pneumatic compression device $80 3 payments
  11. Other $369 13 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

68

Median for Nurse Practitioner: 389

Drug cost

$682

Median for Nurse Practitioner: $21,885

Branded share of claims

73.5%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Clopidogrel Clopidogrel Bisulfate Brand 50 $484
Atorvastatin Calcium Generic 18 $198

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 3 billing codes

Paid by Medicare

$21,870

Medicare's payments for the services billed

Medicare patients

257

Average age 78

Services billed

317

145 women, 112 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 51%
Ischemic heart disease 40%
Chronic kidney disease 35%
Diabetes 32%
Atrial fibrillation 27%
Heart failure 23%
Cancer 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

181 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Connecticut

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record